Skip to main navigation Skip to search Skip to main content

ACE2 as therapy for glomerular disease: the devil is in the detail

  • Michael J. Ross
  • , Masaomi Nangaku

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Angiotensin-converting enzyme 2 cleaves angiotensin (Ang) II to Ang(1-7), which antagonizes the deleterious effects of Ang II. In this issue, 2 groups administered angiotensin-converting enzyme 2 in murine models of kidney disease. Angiotensin-converting enzyme 2 did not improve glomerular injury in 2 models of mild diabetic nephropathy but was partially protective in an Alport syndrome model. These discrepant findings may be explained by the inability of angiotensin-converting enzyme 2 to reach the urinary space in the absence of severe proteinuria.

Original languageEnglish (US)
Pages (from-to)1269-1271
Number of pages3
JournalKidney international
Volume91
Issue number6
DOIs
StatePublished - Jun 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'ACE2 as therapy for glomerular disease: the devil is in the detail'. Together they form a unique fingerprint.

Cite this